Biomea Fusion, Inc. (BMEA) Stock Analysis — Probabli.AI
AI-powered analysis for BMEA (Biomea Fusion, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $1.68 · Market cap: $2.03T · AI outlook: Bullish
Biomea Fusion, Inc. demonstrates strong growth potential due to its robust drug pipeline, positive analyst sentiment, and strategic partnerships. Recent achievements, including the FDA Fast Track designation for its leading drug candidate, support a bullish outlook. Despite competitive pressures and recent executive challenges, the company's growth trajectory is set for significant upsides,…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 1-year price estimates — P10: $1 / P50: $4 / P90: $8
- Biomea Fusion exhibits strong growth potential, evidenced by its consistent earnings beat streak, high analyst price targets, and recent FDA fast track designation for its drug BMF-219. Despite competitive pressures and…
5-Year Outlook
- Bull 65% · Neutral 25% · Bear 10%
- 5-year price estimates — P10: $2 / P50: $8 / P90: $15
SWOT Highlights
- Strength: Strong pipeline with FDA Fast Track designation
- Strength: Successful earnings history with positive surprises
- Risk: Recent executive departures causing strategic concerns
- Risk: Current negative EPS with uncertain near-term profitability
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
7 Wall Street analysts rate BMEA a BUY with a mean price target of $6.8.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
BMEA forecast details · BMEA sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.